High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.

dc.contributor.authorGonzalez, Veronica D
dc.contributor.authorHuang, Ying-Wen
dc.contributor.authorDelgado-Gonzalez, Antonio
dc.contributor.authorChen, Shih-Yu
dc.contributor.authorDonoso, Kenyi
dc.contributor.authorSachs, Karen
dc.contributor.authorGentles, Andrew J
dc.contributor.authorAllard, Grace M
dc.contributor.authorKolahi, Kevin S
dc.contributor.authorHowitt, Brooke E
dc.contributor.authorPorpiglia, Ermelinda
dc.contributor.authorFantl, Wendy J
dc.date.accessioned2025-01-07T16:28:59Z
dc.date.available2025-01-07T16:28:59Z
dc.date.issued2021
dc.description.abstractTubo-ovarian high-grade serous carcinoma (HGSC) is unresponsive to immune checkpoint blockade despite significant frequencies of exhausted T cells. Here we apply mass cytometry and uncover decidual-like natural killer (dl-NK) cell subpopulations (CD56+CD9+CXCR3+KIR+CD3-CD16-) in newly diagnosed HGSC samples that correlate with both tumor and transitioning epithelial-mesenchymal cell abundance. We show different combinatorial expression patterns of ligands for activating and inhibitory NK receptors within three HGSC tumor compartments: epithelial (E), transitioning epithelial-mesenchymal (EV), and mesenchymal (vimentin expressing [V]), with a more inhibitory ligand phenotype in V cells. In cocultures, NK-92 natural killer cells acquire CD9 from HGSC tumor cells by trogocytosis, resulting in reduced anti-tumor cytokine production and cytotoxicity. Cytotoxicity in these cocultures is restored with a CD9-blocking antibody or CD9 CRISPR knockout, thereby identifying mechanisms of immune suppression in HGSC. CD9 is widely expressed in HGSC tumors and so represents an important new therapeutic target with immediate relevance for NK immunotherapy.
dc.identifier.doi10.1016/j.celrep.2021.109632
dc.identifier.essn2211-1247
dc.identifier.pmcPMC8546503
dc.identifier.pmid34469729
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8546503/pdf
dc.identifier.unpaywallURLhttp://www.cell.com/article/S2211124721010755/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27816
dc.issue.number9
dc.journal.titleCell reports
dc.journal.titleabbreviationCell Rep
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number109632
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeResearch Support, U.S. Gov't, Non-P.H.S.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCD9
dc.subjectHGSC
dc.subjectNK cells
dc.subjectNK immunotherapy
dc.subjectT cells
dc.subjectcytokine production
dc.subjectcytotoxicity
dc.subjectdecidual-like
dc.subjectepithelial tumor
dc.subjectepithelial-mesenchymal
dc.subjecthigh-grade serous carcinoma
dc.subjectimmune infiltrate
dc.subjectimmune tolerance
dc.subjecttrogocytosis
dc.subjecttubo-ovarian tumor
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarboplatin
dc.subject.meshCell Line, Tumor
dc.subject.meshCoculture Techniques
dc.subject.meshCytokines
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmune Tolerance
dc.subject.meshKiller Cells, Natural
dc.subject.meshLymphocytes, Tumor-Infiltrating
dc.subject.meshNeoplasms, Cystic, Mucinous, and Serous
dc.subject.meshOvarian Neoplasms
dc.subject.meshPhenotype
dc.subject.meshReceptors, Natural Killer Cell
dc.subject.meshTetraspanin 29
dc.subject.meshTrogocytosis
dc.subject.meshTumor Escape
dc.subject.meshTumor Microenvironment
dc.titleHigh-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number36

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8546503.pdf
Size:
3.11 MB
Format:
Adobe Portable Document Format